7 April 2017
OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid
Cells and Inducing Antitumoral Potent T Memory Response
Nantes, April 5, 2017, 8:00am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today that the Company presented significant results at the AACR* meeting in the very promising field of myeloid/macrophage suppressive cells, an abundant immune cell type infiltrating many tumors and often associated with a poor prognosis.
More information about 2016 Résults : significant milestones, first profit, more growth to come